Last Price$137.11.5%
Market Cap$237.5B
LTM Return on Invested Capital (ROIC)
25.3%
5Y avg
12.1%
Medical - Devices industry
median
(52.6%)
Stock quality & Intrinsic value
7/10
0.3% undervalued
Abbott Laboratories Return on Invested Capital (ROIC)
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Invested Capital (ROIC) | 14.4% | 6.0% | 12.7% | 15.4% | 14.8% | 12.4% | 12.0% | 18.0% | 7.0% | 6.6% | 8.6% | 11.7% | (0.4%) | 5.4% | 7.5% | 8.9% | 13.6% | 13.7% | 10.8% | 25.3% |
Overvalued or undervalued?
Check the intrinsic value for ABT
and see if it's the right time to invest.
Abbott Laboratories (ABT) Return on Invested Capital (ROIC) comparison analysis
General
LTM Return on Invested Capital (ROIC)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Abbott LaboratoriesABT
25.3%
4.6%
134.5%
31.9%
Median Peer Set
11.2%
3.7%
21.3%
11.6%
Insulet CorporationPODD
29.7%
22.1%
101.7%
20.2%
DexCom, Inc.DXCM
21.7%
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
21.6%
(9.4%)
202.2%
76.7%
Stryker CorporationSYK
14.6%
10.2%
(5.8%)
13.2%
Align Technology, Inc.ALGN
14.2%
3.4%
26.0%
11.5%
STERIS plcSTE
8.2%
3.6%
257.9%
7.4%
Boston Scientific CorporationBSX
8.0%
17.6%
16.7%
11.1%
Medtronic plcMDT
7.4%
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
4.5%
3.8%
(9.4%)
11.8%
Koninklijke Philips N.V.PHG
(4.2%)
(0.8%)
83.7%
(3.9%)
ABT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 22,337.8 13.5% | 22,476.3 0.6% | 25,914.2 15.3% | 29,527.6 13.9% | 30,765.0 4.2% | 35,167.0 14.3% | 38,851.0 10.5% | 39,874.0 2.6% | 21,848.0 (45.2%) | 20,247.0 (7.3%) | 20,405.0 0.8% | 20,853.0 2.2% | 27,390.0 31.3% | 30,578.0 11.6% | 31,904.0 4.3% | 34,608.0 8.5% | 43,075.0 24.5% | 43,653.0 1.3% | 40,109.0 (8.1%) | 41,950.0 4.6% |
| Cost of Goods Sold (COGS) | 10,641.1 | 9,815.1 | 11,422.0 | 12,612.0 | 13,209.0 | 14,665.0 | 15,541.0 | 15,120.0 | 10,040.0 | 9,218.0 | 8,747.0 | 9,024.0 | 12,337.0 | 12,706.0 | 13,231.0 | 15,003.0 | 18,537.0 | 19,142.0 | 17,975.0 | 18,706.0 |
% margin | 11,696.7 52.4% | 12,661.2 56.3% | 14,492.2 55.9% | 16,915.5 57.3% | 17,556.0 57.1% | 20,502.0 58.3% | 23,310.0 60.0% | 24,754.0 62.1% | 11,808.0 54.0% | 11,029.0 54.5% | 11,658.0 57.1% | 11,829.0 56.7% | 15,053.0 55.0% | 17,872.0 58.4% | 18,673.0 58.5% | 19,605.0 56.6% | 24,538.0 57.0% | 24,511.0 56.1% | 22,134.0 55.2% | 23,244.0 55.4% |
| Operating Expenses | 7,317.3 | 8,605.0 | 9,913.6 | 11,124.4 | 11,150.0 | 14,101.0 | 17,558.0 | 16,381.0 | 9,179.0 | 8,430.0 | 8,791.0 | 8,644.0 | 13,327.0 | 14,222.0 | 14,141.0 | 14,248.0 | 16,113.0 | 16,149.0 | 15,656.0 | 16,419.0 |
| Research & Development Expenses (R&D) | 1,821.2 | 2,255.3 | 2,505.6 | 2,688.8 | 2,744.0 | 3,725.0 | 4,802.0 | 4,322.0 | 1,452.0 | 1,345.0 | 1,405.0 | 1,422.0 | 2,235.0 | 2,300.0 | 2,440.0 | 2,420.0 | 2,742.0 | 2,888.0 | 2,741.0 | 2,844.0 |
| Selling, General & Administrative Expenses (SG&A) | 5,496.1 | 6,349.7 | 7,408.0 | 8,435.6 | 8,406.0 | 10,376.0 | 12,756.0 | 12,059.0 | 6,936.0 | 6,530.0 | 6,785.0 | 6,672.0 | 9,117.0 | 9,744.0 | 9,765.0 | 9,696.0 | 11,324.0 | 11,248.0 | 10,949.0 | 11,697.0 |
% margin | 4,362.3 19.5% | 2,042.2 9.1% | 4,578.5 17.7% | 5,693.8 19.3% | 6,236.0 20.3% | 6,088.0 17.3% | 5,752.0 14.8% | 8,085.0 20.3% | 2,629.0 12.0% | 2,599.0 12.8% | 2,867.0 14.1% | 3,185.0 15.3% | 1,726.0 6.3% | 3,650.0 11.9% | 4,532.0 14.2% | 5,357.0 15.5% | 8,425.0 19.6% | 8,362.0 19.2% | 6,478.0 16.2% | 6,825.0 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 201.2 | 137.8 | 105.5 | 85.2 | 79.2 | 67.0 | 77.0 | 105.0 | 99.0 | 124.0 | 105.0 | 94.0 | 46.0 | 43.0 | 183.0 | 385.0 | 344.0 |
| Interest Expense | 153.7 | 292.3 | 593.1 | 528.5 | 382.0 | 553.1 | 530.1 | 513.0 | 90.0 | 73.0 | 58.0 | 332.0 | 780.0 | 721.0 | 576.0 | 500.0 | 490.0 | 375.0 | 637.0 | 559.0 |
| Pre-tax Income | 4,619.9 | 2,276.4 | 4,469.6 | 5,856.3 | 7,194.0 | 5,713.0 | 5,199.0 | 6,263.0 | 2,521.0 | 2,518.0 | 3,183.0 | 1,413.0 | 2,231.0 | 2,873.0 | 4,077.0 | 4,968.0 | 8,211.0 | 8,306.0 | 6,664.0 | 7,013.0 |
% effective tax rate | 1,247.9 27.0% | 559.6 24.6% | 863.3 19.3% | 1,122.1 19.2% | 1,448.0 20.1% | 1,087.0 19.0% | 470.0 9.0% | 300.0 4.8% | 138.0 5.5% | 797.0 31.7% | 577.0 18.1% | 350.0 24.8% | 1,878.0 84.2% | 539.0 18.8% | 390.0 9.6% | 497.0 10.0% | 1,140.0 13.9% | 1,373.0 16.5% | 941.0 14.1% | (6,389.0) (91.1%) |
% margin | 3,372.1 15.1% | 1,716.8 7.6% | 3,606.3 13.9% | 4,880.7 16.5% | 5,745.8 18.7% | 4,626.2 13.2% | 4,728.0 12.2% | 5,963.0 15.0% | 2,576.0 11.8% | 2,284.0 11.3% | 4,423.0 21.7% | 1,400.0 6.7% | 477.0 1.7% | 2,368.0 7.7% | 3,687.0 11.6% | 4,495.0 13.0% | 7,071.0 16.4% | 6,933.0 15.9% | 5,723.0 14.3% | 13,402.0 31.9% |
| EPS | 2.17 | 1.12 | 2.34 | 3.16 | 3.72 | 2.99 | 3.01 | 3.78 | 1.66 | 1.51 | 3.00 | 0.95 | 0.27 | 1.35 | 2.07 | 2.52 | 3.97 | 3.94 | 3.30 | 7.74 |
| Diluted EPS | 2.16 | 1.12 | 2.31 | 3.13 | 3.70 | 2.97 | 3.01 | 3.75 | 1.64 | 1.50 | 2.94 | 0.94 | 0.27 | 1.34 | 2.06 | 2.50 | 3.94 | 3.91 | 3.27 | 7.67 |
% margin | 6,220.2 27.8% | 4,251.3 18.9% | 6,433.4 24.8% | 8,223.6 27.9% | 9,493.9 30.9% | 9,138.3 26.0% | 9,260.7 23.8% | 3,496.0 8.8% | 3,452.0 15.8% | 4,216.0 20.8% | 4,833.0 23.7% | 3,070.0 14.7% | 6,132.0 22.4% | 7,116.0 23.3% | 7,771.0 24.4% | 8,789.0 25.4% | 12,742.0 29.6% | 12,380.0 28.4% | 10,605.0 26.4% | 10,834.0 25.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Abbott Laboratories's Return on Invested Capital (ROIC)?
As of today, Microsoft Corp's last 12-month Return on Invested Capital (ROIC) is 25.3%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Return on Invested Capital (ROIC) for Abbott Laboratories have been 13.6% over the past three years, and 12.7% over the past five years.
2) Is Abbott Laboratories's Return on Invested Capital (ROIC) Good?
As of today, Abbott Laboratories's Return on Invested Capital (ROIC) is 25.3%, which is higher than industry median of (52.6%). It indicates that Abbott Laboratories's Return on Invested Capital (ROIC) is Good.